Quarterly report [Sections 13 or 15(d)]

Note 12 - Contingent Liabilities (Details Textual)

v3.25.1
Note 12 - Contingent Liabilities (Details Textual) - USD ($)
6 Months Ended
Feb. 29, 2024
Mar. 31, 2025
Sep. 30, 2024
Accounts Payable, Current   $ 2,205,474 $ 2,259,668
Other Liabilities, Noncurrent   3,364,425 $ 4,461,920
Damages from Product Defects [Member]      
Product Liability Contingency, Loss Exposure Not Accrued, Best Estimate   10,000,000  
Loss Contingency, License and Purchase Agreements [Member]      
Loss Contingency Accrual   0  
Loss Contingency, Commercial Dispute [Member] | Research and Development Liability [Member]      
Accounts Payable, Current   1,200,000  
Other Liabilities, Noncurrent   $ 3,400,000  
Loss Contingency, Commercial Dispute [Member] | Product, Sabizabulin Drug [Member]      
Loss Contingency, Damages Sought, Value $ 10,000,000    
Loss Contingency Accrual, Product Liability, Net 8,300,000    
Loss Contingency, Commercial Dispute [Member] | Product, Sabizabulin Drug [Member] | Payment Arrangement, Due Upon Execution of Agreement [Member]      
Loss Contingency Accrual, Product Liability, Net 2,300,000    
Loss Contingency, Commercial Dispute [Member] | Product, Sabizabulin Drug [Member] | Payment Arrangement, Monthly Installments,One [Member]      
Loss Contingency Accrual, Product Liability, Net $ 3,500,000    
Product Liability Contingency, Disbursement Period, Estimate, Accrued (Month) 48 months    
Loss Contingency, Commercial Dispute [Member] | Product, Sabizabulin Drug [Member] | Payment Arrangement, Balance by December 31, 2025 [Member]      
Loss Contingency Accrual, Product Liability, Net $ 2,500,000    
Loss Contingency, Commercial Dispute [Member] | Product, Sabizabulin Drug [Member] | Payment Arrangement, Monthly Installments, Two [Member]      
Product Liability Contingency, Disbursement Period, Estimate, Accrued (Month) 24 months